The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care. The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on five key areas: 1) oncology pharmacy practice as a pharmacy specialty; 2) contributions to patient care; 3) oncology pharmacy practice management; 4) education and training; and 5) contributions to oncology research and quality initiatives to involve the OPT. This position statement advocates that: 1) the OPT be fully incorporated into the MHT to optimize patient care; 2) educational and healthcare institutions develop programs to continually educate OPT members; and 3) regulatory authorities develop certification programs to recognize the unique contributions of the OPT in cancer patient care.
HolleLMMichaudLB.Oncology pharmacists in health care delivery: vital members of the cancer care team. J Oncol Pract2014;
10: e142–3145.
3.
SinclairAEyreCPettsH, et al.
Introduction of pharmacy technician onto a busy oncology ward as part of a nursing team. Eur J Hosp Pharm2018;
25: 92–95.
4.
BoeskenTAMcKinneyKCWiestMD.Improving efficiency of financial authorization by establishing a standard infusion workflow. Am J Health-Syst Pharm2019;
76: 780–783.
5.
ChengVMarkarianAde LemosML, et al.
Evaluation of the role of pharmacy technicians in reviewing the eligibility for oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients. J Oncol Pharm Pract2019;
25: 1167–1173.
6.
LoACoMLoC, et al.
Specialized pharmacy oncology technician: experience at the ridge meadows hospital. Can J Hosp Pharm2010 2010;
63: 138–141.
7.
MattinglyANMattinglyTJ2nd.Advancing the role of the pharmacy technician: a systematic review. J Am Pharm Assoc2003;
58: 94–108.
8.
NevilleHBroadfieldLHardingC, et al.
Chemotherapy order entry by a clinical support pharmacy technician in an outpatient medical day unit. Can J Hosp Pharm2016;
69: 202–208.
IshikawaKKatzaMHill-BesinqueK.Graduate programs in advanced pharmacy practice in oncology in Japan. Am J Pharm Educ2010;
74: 111.
21.
ValgusJMFasoAGregoryKM, et al.
Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center. Am J Health-Syst Pharm2011;
68: 613–619.
22.
BattisBCliffordLHuqM, et al.
The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy. J Oncol Pharm Pract2017;
23: 582–590.
23.
HansenEAPietkiewiczJMBlumBL.Evaluation of the feasibility and utility of a pharmacist-centered collaborative drug therapy management program for oncology-based symptom management. J Pharm Pract2016;
29: 206–211.
24.
WongS-FBounthavongMNguyenCP, et al.
Outcome assessments and cost avoidance of an oral chemotherapy management clinic. J Natl Compr Cancer Netw JNCCN2016;
14: 279–285.
25.
YeohTTSiPChewL.The impact of medication therapy management in older oncology patients. Support Care Cancer2013;
21: 1287–1293.
26.
LamMSCheungN.Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract2016;
22: 741–748.
27.
IiharaHIshiharaMMatsuuraK, et al.
Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract2012;
18: 753–760.
28.
PeriasamyUMohd SidikSRampalL, et al.
Effect of chemotherapy counseling by pharmacists on quality of life and psychological outcomes of oncology patients in Malaysia: a randomized control trial. Health Qual Life Outcomes2017;
15: 104.
29.
WongS-FBounthavongMNguyenC, et al.
Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm2014;
71: 960–965.
30.
RandolphLAWalkerCKNguyenAT, et al.
Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center. J Oncol Pharm Pract2018;
24: 3–8.
31.
RuderADSmithDLMadsenMT, et al.
Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic?J Oncol Pharm Pract2011;
17: 425–432.
32.
AliKAl-QuteimatONaseemR, et al.
Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in paediatric haematology-oncology and transplant clinic: assessment and significance. J Oncol Pharm Practice2020; DOI: 10.1177/1078155220934167.
33.
DarlingJORaheemFCarterKC, et al.
Evaluate of a pharmacist led oral chemotherapy clinic: a pilot program in the gastrointestinal clinic at an academic medical center. Pharmacy2020;
8: 46.
34.
LauKMSaundersIMSaccoAG, et al.
Evaluation of pharmacist interventions in a head and neck medical oncology clinic. J Oncol Pharm Pract2020; DOI: 10.1177/1078155219897129
35.
DuarteNCBarbosaCRTavaresMGR, et al.
Clinical oncology pharmacist: effective contribution to patient safety. J Oncol Pharm Pract2019;
25: 1665–1674.
36.
SweissKWirthSMSharpL, et al.
Collaborative physician-pharmacist-managed multiple myeloma clinic improves guideline adherence and prevents treatment delays. J Oncol Pharm2018;
14: 684–681.
37.
GeumMJAhn JHKimJS, et al.
Interprofessional collaboration between a multidisciplinary palliative care team and the team pharmacist on pain management. Am J Hospice Palliat Med2019;
36: 616–622.
38.
CrulMOosterhofP.The oncology pharmacist as part of the palliative treatment team. Int J Pharm Pract2020;
38: 92–96.
39.
LiuJWangCChenX, et al.
Evaluation of pharmacist interventions as part of a multidisciplinary cancer pain management team in a Chinese academic medical center. J Am Pharm Assoc2020;
60: 76–80.
40.
DingHZhengXKongS, et al.
Multidisciplinary intervention incorporating pharmacists in management of opioid-naïve patients with moderate cancer pain. E J Cancer Care2020;
29: e13225.
41.
De GregoriJPistrePBoutetM, et al.
Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department. J Oncol Pharm Pract2020;
26: 1172–1179.
42.
ViraniASchleiZGleasonC, et al.
Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic. Clin Lymph Myeloma Leuk2020; 20: e543–e546.
43.
HoLAkadaKMessnerH, et al.
Pharmacist’s role in improving medication safety for patients in an allogeneic hematopoietic cell transplant ambulatory clinic. Can J Hosp Pharm2013;
66: 110–117.
44.
DuffyAPBembenNNLiJ, et al.
Facilitating home hospice transitions of care in oncology: evaluation of clinical pharmacists’ interventions, hospice program satisfaction, and patient representation rates. Am J Hospice Palliat Med2018;
35: 1181–1187.
45.
BosnakASBirandNDikerO, et al.
The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy. J Oncol Pharm Pract2019;
25: 1312–1320.
46.
SuzukiHSuzukiSKamataH, et al.
Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy. J Oncol Pharm Pract2019;
25: 1558–1563.
47.
KucukEBayraktar-EkinciogluAErmanM, et al.
Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. J Oncol Pharm Pract2020;
26: 595–602.
48.
Bayraktar-EkinciogluAKucukE.The differences in the assessments of side effects at an oncology outpatient clinic. Int J Clin Pharm2018;
40: 386–393.
49.
SavasMBayraktar-EkinciogluACelebiN.An evaluation of cancer patients' opinions about use of opioid analgesics and the role of clinical pharmacist in patient education in Turkey. Int J Clin Pharm2020; 2021; 43: 375–382. doi: 10.1007/s11096-020-01098-x.
50.
KandemirEABayraktar-EkinciogluAKilickapS.Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy. Support Care Cancer2021;
29: 1699–1709.
51.
Tecen-YucelKBayraktar-EkinciogluAKılıckapS, et al.
Clinical pharmacy practices in oncology patients treated with tyrosine kinase inhibitors. Int J Hematol Oncol (UHOD)2018;
28: 53–60.
52.
CoutsouvelisJSiderovJTeyAY, et al.
The impact of pharmacist-led strategies implemented to reduce errors related to cancer therapies: a systematic review. J Pharm Pract Res2020;
50: 466–580.
53.
TanzerKDintznerM.Promoting professionalism socialization with the experiential curriculum: implementation of a high-stakes professionalism rubric. Am J Pharm Educ2017;
81: 19.
54.
American Pharmacists Association Foundation. Medication therapy management, www.aphafoundation.org/medication-therapy-management#. :∼:text=Medication%20Therapy%20Management%20%28MTM%29%201%20Goal.%20To%20describe,Publication.%20…%206%20Looking%20to%20the%20Future.%20 (2020, accessed 25 July 2020).
55.
CohenMRAndersonRWAttilioRM, et al.
Preventing medication errors in cancer chemotherapy. Am J Health-Syst Pharm1996;
53: 737–746.
56.
NeussMNGilmoreTRBeldersonKM, et al.
2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy administration safety standards, including standards for pediatric oncology. J Oncol Prac2016;
12: 1262–1271.
57.
HawkinsSFNickmanNAMorseJE.The paradox of safety in medication management. Qual Health Res2017;
27: 1910–1923.
58.
FeltonMvan LondenGJMarcumZA.Medication adherence to oral cancer therapy: the promising role of the pharmacist. J Oncol Pharm Pract2014;
22: 378–381.
59.
SchneiderSMHessKGosselinT.Interventions to promote adherence with oral agents. Semin Oncol Nurs2011;
27: 133–141.
60.
BaldoPFornasierGCiofliL, et al.
Pharmacovigilance in oncology. Int J Clin Pharm2018;
40: 832–841.
61.
van LeeuwenRFSwartELBovenE, et al.
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol2011;
22: 2334–2341.
62.
van LeeuwenRWFBrundelDHSNeefC, et al.
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer2013;
108: 1071–1078.
63.
RiechelmannRPMoreiraFSmaletzÒ, et al.
D. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol2005;
56: 286–290.
64.
HainesSTPittengerALStolteSK, et al.
Core entrustable professional activities for new pharmacy graduates. Am J Pharm Educ2017;
81: S2.
65.
ShahNNCasellaECapozziD, et al.
Improving the safety of oral chemotherapy at an academic medical center. J Oncol Pract2016;
12: e71–e76.
66.
DelpeuchALevequeDGourieuxB, et al.
Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res2015;
35: 457–460.
67.
Lopez-MartinCGarrido SilesMAlcaide-GarciaJ, et al.
Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm2014;
36: 1251–1259.
68.
BalkTEvan der SijsIHvan GelderT, et al.
Drug-drug interactions in pediatric oncology patients. Pediatr Blood Cancer2017;
64: e26410.
69.
KovacevicTKovacevicSVStaneticM, et al.
Impact of pharmacist’s intervention on decreasing erolotinib interactions in the treatment of lung cancer patients in low resource settings. J Oncol Pharm Pract2020; DOI: 10.1177/1078155220921545.
70.
HaanenJBAGCarbonnelFRobertC, et al.
Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol2017;
28: iv119–iv142.
71.
NeelapuSSTummalaSKebriaeiP, et al.
Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol2018;
15: 47–62.
72.
SloanFAGelbandH (eds). Cancer control opportunities in low- and Middle-Income countries.
Washington, DC:
National Academies Press (US), 2007.
73.
BoechlerBLDespinsBRHolmesJ, et al.
Advocacy in pharmacy: changing “what is” into “what should be. Can Pharm J (Ott)2015;
148: 138–141. (May):
CarringtonCStoneLKoczwaraB, et al.
The clinical oncological society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia Pac J Clin Oncol2010;
6: 220–237.
79.
BergsbakenJRomanDEarlMA, et al.
ASHP-HOPA guidelines on the roles and responsibilities of the pharmacy technician in ambulatory oncology pharmacy. Am S Health-Syst Pharm2018;
75: 1304–1311.
American Society of Health-System Pharmacists.
ASHP guidelines on preventing medication errors in hospitals. Am J Health-Syst Pharm2018;
75: 1493–1517.
82.
American Society of Hospital Pharmacists.ASHP guidelines on preventing medication errors with antineoplastic agents.Am J Health-Syst Pharm2002;
59: 1648–1668, 1517.
83.
ISOPP standards of practice.
Safe handling of cytotoxics. J Oncol Pharm Pract2007;
13: 181.
84.
AminSAvilaJBoronM, et al. HOPA investigational drug service best practice standards, hoparx,org/images/hopa/resource-library/guidelines-standards/HOPA16_IDS_Guidelines.reviewed_2018.pdf (2014, accessed 22 June 2020).
GoldspielBHoffmanJMGriffithNL, et al.
ASHP guidelines on preventing medication errors with chemotherapy and biotherapy. Am J Health-Syst Pharm2015;
72: e6–35.
87.
PowerLACoyneJW.ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm2018;
75: 1996–2031.
GoodinSGriffithNChenB, et al.
Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract2011;
7: 7–12.
The National Institute for Occupational Safety and Health. Hazardous drug exposures in health care | NIOSH | CDC, www.cdc.gov/niosh/topics/hazdrug/default.html (2018, accessed 22 June 2020).
United States Pharmacopeia [USP] Compounding Standards (including <795>, <797> and <800> standards), www.usp.org/compounding (accessed 3 December 2020).
101.
MacklerESegalEMMulunehB, et al.
Hematology/oncology pharmacist association best practices for the management of oral oncolytic therapy: pharmacy practice standard. J Oncol Pract2018;
2019: 346e–3355.e.
AlwoodMStanleyAWrightP.The cytotoxics handbook. 4th ed.
UK:
Radcliffe Medical Press, 2002.
108.
Ministry of Health Indonesia. 2010. Peraturan Menteri Kesehatan No 1799 tentang Industri Farmasi.
109.
Accreditation Commission on Healthcare. Pharmacy compounding accreditation board (PCAB), www.achc.org/compounding-pharmacy.html (2020, accessed 22 June 2020).
110.
McKeeMFreiBLGarciaA, et al.
Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract2011;
17: 387–394.
111.
CrespoATyszkaM.Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit. J Oncol Pharm Pract2017;
23: 243–248.
112.
SubongkotSSrisawatSJohnsN, et al.
Outcome of chemotherapy counseling in oncology patients by pharmacist. Isan J Pharm Sci2009;
5: 34–45.
113.
ToporDRDickeyCStonestreetL, et al.
Interprofessional health care education at academic medical centers: using a SWOT analysis to develop and implement programming. MedEdPORTAL2018;
14: 10766.
114.
BresslerTPersicoL.Interprofessional education: partnerships in the education process. Nurse Educ Pract2016;
16: 144–147.
